Form 4: Penumbra Exec Granted RSUs, Merger Clause Noted

Penumbra's EVP, General Counsel & Secretary, Johanna Roberts, received two grants of restricted stock units, with accelerated vesting tied to a potential merger with Boston Scientific.

Summary

• Johanna Roberts, EVP, General Counsel & Secretary of Penumbra Inc. (PEN), was granted a total of 5,260 Restricted Stock Units (RSUs) across two separate transactions.
• On February 13, 2026, 2,630 RSUs were granted, with 1/4 of these RSUs scheduled to vest equally on February 15, 2026, February 15, 2027, February 15, 2028, and February 15, 2029, subject to continued service.
• On February 17, 2026, an additional 2,630 RSUs were granted, with 1/4 of these RSUs scheduled to vest equally on an annual basis, beginning on February 15, 2027, subject to continued service.
• A significant clause indicates that if the 'Closing' (as defined in an Agreement and Plan of Merger dated January 14, 2026, among Penumbra, Boston Scientific Corporation, and Pinehurst Merger Sub, Inc.) occurs, any unvested RSUs will fully vest, subject to continued service through such date.
• On February 15, 2026, 482 shares of Penumbra Common Stock were withheld by the Issuer at a price of $339.30 per share to satisfy tax withholding obligations in connection with the vesting of previously granted RSUs.
• Following these transactions, Johanna Roberts beneficially owns 67,484 shares of Penumbra Common Stock, a portion of which remains subject to vesting.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the significant RSU grants to a key executive, which aligns management incentives with shareholder value. The explicit mention of a potential merger with Boston Scientific, triggering accelerated vesting, introduces a strong strategic element that could be highly beneficial for shareholders if the transaction materializes.

Positives

• Grant of 5,260 Restricted Stock Units (RSUs) to a key executive, Johanna Roberts, aligns management's interests with long-term shareholder value.
• The potential for accelerated vesting of all unvested RSUs upon the closing of the proposed merger with Boston Scientific Corporation provides a strong incentive for the executive to facilitate the transaction.
• Increased beneficial ownership for the EVP, General Counsel & Secretary to 67,484 shares, demonstrating continued commitment to the company.

Negatives

• 482 shares of Common Stock were withheld by the Issuer at $339.30 per share to satisfy tax withholding obligations, representing a reduction in the executive's direct share count from a previous vesting event.

Risks

• The filing explicitly mentions a potential merger with Boston Scientific Corporation and Pinehurst Merger Sub, Inc., dated January 14, 2026. The failure of this merger to close could impact the accelerated vesting of RSUs and potentially the company's strategic direction.
• The 'continued service' condition for both regular and accelerated vesting means the executive must remain employed by Penumbra to realize the full benefit of the RSU grants.

Future Outlook

The future outlook for Johanna Roberts' equity compensation is tied to both her continued service and the potential closing of the merger agreement with Boston Scientific Corporation. If the merger closes, all unvested RSUs will accelerate vesting, providing a significant incentive for the executive. Otherwise, vesting will proceed according to the established annual schedule through February 2029.

Management Comments

• On February 13, 2026, the Reporting Person was granted 2,630 restricted stock units (RSUs) under the Issuer's Amended and Restated 2014 Equity Incentive Plan.
• Shares were withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs granted to the Reporting Person.
• On February 17, 2026, the Reporting Person was granted 2,630 RSUs under the Issuer's Amended and Restated 2014 Equity Incentive Plan.

Industry Context

StockSavvy.ai notes that executive RSU grants are a standard component of compensation packages in the medical device industry, designed to align executive interests with long-term shareholder value. The explicit mention of accelerated vesting tied to a merger with Boston Scientific Corporation is a critical detail, suggesting that Penumbra may be actively pursuing or nearing a significant strategic transaction. This could signal a potential consolidation trend within the medical technology sector, where larger players like Boston Scientific seek to acquire innovative companies to expand their product portfolios or market share.

Comparison to Industry Standards

• This Form 4 filing details an insider transaction, specifically RSU grants and tax-related share withholding. Direct comparison to industry-wide financial performance or operational benchmarks is not applicable.
• However, the structure of RSU grants with performance or event-based acceleration (like a merger) is a common practice in executive compensation across the technology and healthcare sectors, including companies like Medtronic or Abbott Laboratories, to incentivize key personnel during strategic transitions.

Stakeholder Impact

• Shareholders: Potential positive impact from increased executive alignment and the strategic implications of a potential merger with Boston Scientific. Minor dilution from RSU grants is expected.
• Employees: The merger clause could signal broader strategic changes or potential acquisition, which might impact other employees.
• Management: Johanna Roberts benefits directly from the RSU grants and the potential for accelerated vesting.

Next Steps

• Continued service by Johanna Roberts to ensure vesting of RSUs.
• Potential closing of the merger agreement with Boston Scientific Corporation, which would trigger accelerated vesting of unvested RSUs.
• Annual vesting of RSUs on February 15, 2027, February 15, 2028, and February 15, 2029, subject to continued service.

Key Dates

Recommendation

The filing reveals a significant potential merger with Boston Scientific, which could be a major catalyst for Penumbra's stock. While the RSU grants themselves are standard executive compensation, the merger clause introduces substantial upside potential. However, without further details on the merger terms (e.g., valuation, synergies, likelihood of closing), a 'hold' recommendation is prudent. Investors should monitor for further announcements regarding the Boston Scientific merger, as its successful completion would likely warrant a re-evaluation towards a 'buy' due to potential acquisition premium, while a failure could lead to downward pressure.

Keywords

Penumbra Inc, PEN, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Incentive Plan, Executive Compensation, Merger Agreement, Boston Scientific, Corporate Governance, Stock Grant, Vesting, Johanna Roberts